171 related articles for article (PubMed ID: 21212425)
21. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A; Pressiani T; Citterio G; Rossoni G; Donadoni G; Pozzi F; Rimassa L; Personeni N; Bozzarelli S; Rossoni G; Colombi S; De Braud FG; Caligaris-Cappio F; Lambiase A; Bordignon C
Br J Cancer; 2010 Sep; 103(6):837-44. PubMed ID: 20717115
[TBL] [Abstract][Full Text] [Related]
22. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.
Patel A; Sun W
Curr Treat Options Oncol; 2014 Sep; 15(3):380-94. PubMed ID: 24838298
[TBL] [Abstract][Full Text] [Related]
23. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Shao YY; Huang CC; Lin SD; Hsu CH; Cheng AL
Clin Cancer Res; 2012 Jul; 18(14):3992-7. PubMed ID: 22623732
[TBL] [Abstract][Full Text] [Related]
24. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
25. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.
Tanaka S; Arii S
J Gastroenterol; 2011 Mar; 46(3):289-96. PubMed ID: 21350811
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of the peripheral blood absolute monocyte count in patients with locally advanced or metastatic hepatocellular carcinoma receiving systemic chemotherapy.
Lin GN; Jiang XM; Peng JW; Xiao JJ; Liu DY; Xia ZJ
Asian Pac J Cancer Prev; 2014; 15(15):6387-90. PubMed ID: 25124630
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
[TBL] [Abstract][Full Text] [Related]
30. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Kuczynski EA; Kerbel RS
Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
[TBL] [Abstract][Full Text] [Related]
31. Tumor markers for early diagnosis for brain metastasis of hepatocellular carcinoma: A case series and literature review for effective loco-regional treatment.
Kamimura K; Kobayashi Y; Takahashi Y; Abe H; Kumaki D; Yokoo T; Kamimura H; Sakai N; Sakamaki A; Abe S; Takamura M; Kawai H; Yamagiwa S; Terai S
Cancer Biol Ther; 2017 Feb; 18(2):79-84. PubMed ID: 28045618
[TBL] [Abstract][Full Text] [Related]
32. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study.
Du X; Chen D; Lin Z; Dong Z; Lu Y; Liu L; Wu D
J BUON; 2019; 24(5):1956-1963. PubMed ID: 31786861
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with hepatocellular carcinoma and extrahepatic metastasis.
Lee HS
Dig Dis; 2011; 29(3):333-8. PubMed ID: 21829026
[TBL] [Abstract][Full Text] [Related]
36. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.
Ribatti D; Nico B; Mangieri D; Longo V; Sansonno D; Vacca A; Dammacco F
Histol Histopathol; 2007 Mar; 22(3):285-9. PubMed ID: 17163402
[TBL] [Abstract][Full Text] [Related]
37. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.
Tanaka S; Arii S
Int J Clin Oncol; 2010 Jun; 15(3):235-41. PubMed ID: 20505971
[TBL] [Abstract][Full Text] [Related]
38. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
39. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
40. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
